Ετικέτες

Πέμπτη 20 Δεκεμβρίου 2018

Opioid Prescribing Practice and Needs in Thyroid and Parathyroid Surgery. | Endocrine Surgery | JAMA Otolaryngology–Head & Neck Surgery | JAMA Network

patients undergoing thyroid and parathyroid surgery need very little, if any, postoperative opioids
https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2705986?guestAccessKey=84f31292-2ffb-48b9-b95e-355f9b79296c&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jamaotolaryngology&utm_content=etoc&utm_term=122018

What is the postoperative opioid prescribing practice and true need for opioids after thyroidectomy and parathyroidectomy?

Findings  In a cohort study of 1702 patients undergoing 1765 thyroidectomy and parathyroidectomy procedures, the mean postoperative prescribed dose of opioids was shown to be significantly reduced after initiation of preoperative patient education and use of nonopioid medications. In the last quarter of 2017, the mean (SD) dose prescribed was 19.90 (26.60) morphine milligram equivalents for parathyroidectomy, 56.72 (61.65) morphine milligram equivalents for hemithyroidectomy, and 68.15 (68.47) morphine milligram equivalents for total thyroidectomy.

Meaning  Results of the study suggest that patients undergoing thyroid and parathyroid surgery need little opioid treatment postoperatively.

Abstract

Importance  In recent years, the medical community's inadvertent contribution to opioid addiction has been recognized.

Objective  To determine the opioid prescribing practices and opioid needs for patients undergoing thyroid and parathyroid surgery to help reduce postoperative opioid administration.

Design, Setting, and Participants  This retrospective cohort study included 1788 opioid-naive patients who underwent thyroid and parathyroid surgery from January 1, 2012, through December 31, 2017, at the high-volume academic endocrine surgery center at Oregon Health and Sciences University. Patients with long-term opioid treatment and those who underwent other head and neck procedures or robotic thyroidectomy were excluded. For analysis, 1765 procedures were available (723 parathyroidectomy, 400 hemithyroidectomy, and 642 total thyroidectomy).

Main Outcomes and Measures  The quantity of prescribed opioids was determined in morphine milligram equivalents (MME). Opioid refill data after discharge were also analyzed. Patients were then divided into past (1336 in group 1 [January 1, 2012, to September 30, 2016]) and current (429 in group 2 [October 31, 2016, to December 31, 2017]) prescribing practices. For each procedure, the mean quantity prescribed for each group, difference between the means, 95% CI for the difference, and effect size were calculated.

Results  A total of 1702 patients (80.0% female [n = 1361]; mean age, 51.2 years [range, 7-97 years]) undergoing 1765 procedures were included in the analysis. For parathyroidectomy, the mean (SD) opioid quantity prescribed was 176.20 (86.66) MME in group 1 vs 80.08 (74.43) MME in group 2 (effect size, 1.139); for hemithyroidectomy, 204.65 (112.24) MME in group 1 vs 112.24 (102.31) MME in group 2 (effect size, 0.842); and for total thyroidectomy, 214.87 (161.09) MME for group 1 vs 102.29 (87.72) MME for group 2 (effect size, 0.754). In the last quarter of 2017, the numbers of patients discharged without any opioid prescription were 15 of 26 (57.5%) for parathyroidectomy, 12 of 32 (37.5%) for hemithyroidectomy, and 9 of 27 (33.3%) for total thyroidectomy. Patient calls requesting pain medications for group 2 were similar or fewer, depending on the procedure. Those who were prescribed less than 75.0 MME postoperatively did not call for additional opioid prescriptions.

Conclusions and Relevance  Our study suggests that patients undergoing thyroid and parathyroid surgery need little, if any, postoperative opioids.

Introduction

The epidemic of opioid abuse has continued to plague the United States. The rate of drug overdose deaths increased from 6.1 per 100 000 standard population in 1999 to 16.3 per 100 000 in 2015, with an overall mean increase of 5.5% per year.1 According to the Centers for Disease Control and Prevention, approximately 64 000 deaths in the United States were due to opioid overdose in 2016.2

More recently awareness of this epidemic and recognition of the medical community's inadvertent contribution to the problem with previously accepted standard opioid prescribing practices have increased. From 2006 to 2016, the mean duration of opioid prescribed increased from 13.3 to 18.1 days per prescription, an overall 35.7% increase. The rate increased annually by 4.4% from 2006 to 2008.1 Recognizing this increase as a serious health problem, the Centers for Disease Control and Prevention in 2016 issued guidelines for primary care physicians treating chronic pain with opioids.3 The guidelines state that because long-term opioid dependence begins with acute pain treatment, opioid prescribing for acute pain should not exceed the quantity needed. These guidelines are particularly relevant to surgeons because most postsurgical patients will have an acute period of postoperative pain. Unfortunately, we have a paucity of surgery-specific opioid prescribing guidelines in the literature. As a result, wide variation in opioid prescribing patterns exists among surgeons of various specialties.4-7 Furthermore, the amount prescribed is usually excessive, because studies have shown that as many as 71% of opioids prescribed postoperatively are not taken by the patient.4 In a retrospective review of a large cohort of privately insured patients in the United States undergoing major and minor surgical procedures, Brummett et al8 reported that the incidence of persistent opioid use 90 days after minor surgery in opioid-naive patients was 6%. Within this group, the incidence of persistent opioid use in patients undergoing thyroidectomy was 4.5%; for parathyroidectomy, 6%. Underlying psychiatric conditions, such as depression, are risk factors for long-term opioid use. As such, if patients are prescribed larger quantities than their real need, they may continue to use their prescribed excess opioids to alleviate depression and emotional pain, thus increasing the risk of addiction. A paucity of research quantitatively characterizes the mean volume of opioid medication that patients are prescribed after discharge from endocrine surgery. This retrospective study was conducted to determine opioid prescribing practices and opioid needs in patients who underwent thyroid and parathyroid surgery at a single institution performing high-volume endocrine procedures.

Methods

We performed a retrospective cohort study of all opioid-naive patients who underwent thyroid and parathyroid operations at the Oregon Health and Science University (OHSU), Portland, from January 1, 2012, through December 31, 2017. This protocol was approved by institutional review board of OHSU, which did not require informed consent for this retrospective review.

The electronic medical record at OHSU was queried by Current Procedural Terminology codes 60220, 60240, 60252, 60270, and 60500 during the study period. These codes reflect the specific operations of total thyroidectomy, hemithyroidectomy, and parathyroidectomy. The quantity of opioids prescribed on discharge was then collected from each patient's discharge medication list. Those who underwent sternotomy, robotic thyroidectomy, concurrent modified neck dissection, or other head and neck procedures such as tracheotomy or tracheal resection were excluded, as well as those who were previously taking opioids for chronic pain and who were admitted for more than 2 nights. Those who underwent concurrent thyroidectomy and parathyroidectomy were categorized as undergoing thyroidectomy (hemithyroidectomy or total thyroidectomy).

In late September of 2016, several surgeons within the Thyroid and Parathyroid Center at OHSU made a concerted effort to decrease opioid prescribing in patients undergoing thyroid and parathyroid operations. Therefore, for data analysis, the groups were then subdivided into past (group 1 [January 1, 2012, to September 30, 2016]) and current (group 2 [October 31, 2016, to December 31, 2017]) prescribing practices. The concerted effort to reduce opioid prescribing included preoperative patient counselling regarding pain management, multimodality nonopioid pain management, and work with nursing on assessing pain based on functional status rather than a 1- to 10-point scale and avoiding opioid administration when possible. The following statement typifies the preoperative discussion with patients regarding postoperative pain:

You will have some soreness around the surgical site and mild discomfort when you swallow. We typically treat that with ice packs, Tylenol, and ibuprofen. It is unlikely that you will need anything more than that. We will see how you do postop and make sure that you are doing fine with this regimen. We want to avoid opioids as much as possible with this kind of surgery because they can cause nausea and vomiting, which is not ideal with a neck incision. You may also have some sore throat, which is best treated with throat lozenges.

The quantity of opioids prescribed in recovery if the patient is discharged the same day or on the floor if admitted overnight was generally used to determine the quantity of opioids to be prescribed on discharge. The total quantity of opioids prescribed was calculated by multiplying the strength of the prescribed opioids by the quantity dispensed. For standardization of data analysis, the total amount prescribed was converted to morphine milligram equivalents (MME) by multiplying the total milligrams of prescribed opioid with a standard conversion factor for the specific medication (ie, 0.15 for codeine phosphate; 1.0 for hydrocodone bitartrate; 1.5 for oxycodone hydrochloride; 4.0 for hydromorphone hydrochloride; and 2.4 for transdermal fentanyl citrate). Calls for pain medications after discharge were also captured by searching the database for opioid prescriptions dispensed that are recorded in the patient's medication list within 3 weeks of discharge. All medical records meeting these criteria were individually reviewed to confirm a refill and incorporated into the analysis. The primary outcome was the median amount of MME administered as grouped by study period and operation type.

Statistical analysis was performed by determining the mean and SD using Excel (version 15.23; Microsoft Corporation) for all procedures and each type of surgery. For each type of procedure, the effect size and 95% CI were calculated for the mean difference between groups 1 and 2. Because of the sample size difference, the Hedges g value9 was used to determine the effect size for the difference in percentage of patients in groups 1 vs 2 who called in for additional pain medication. The effect size is considered small if g = 0.2, medium if g = 0.5, and large if g = 0.8. The effect size for the difference in percentage of calls for opioids after discharge between groups 1 and 2 was also calculated.

Results

During the study period, 1788 patients underwent head and neck endocrine surgery, of whom 86 were excluded owing to reasons stated in the methods section, leaving 1702 patients (1361 female [80.0%] and 341 male [20.0%]; mean age, 51.2 years [range, 9-97 years]). Sixty-three patients underwent 2 procedures, for example hemithyroidectomy followed by completion thyroidectomy at a later date. Therefore, the total number of procedures during the entire study period included was 1765. Between the 2 periods, 1336 patients were in group 1 and 429 were in group 2. The breakdown of procedures are as follows: 723 parathyroidectomy procedures, 400 hemithyroidectomy procedures, and 642 total thyroidectomy procedures. The patient population is summarized in Table 1.

When looking at opioid prescription amounts, a large decrease in the total amount of opioids prescribed at discharge occurred between groups 1 and 2 for each procedure. For the 3 different procedures, the mean opioid quantity prescribed in each group, SD, the difference between the means, 95% CI, and effect size for the mean difference are summarized in Table 2. For each of the 3 procedures, the total MME prescribed each quarter steadily decreased for group 2 (Figure). In the last quarter of 2017, the mean (SD) quantity prescribed was 19.90 (26.60) MME for parathyroidectomy, 56.72 (61.65) MME for hemithyroidectomy, and 68.15 (68.47) MME for total thyroidectomy. During this last quarter, patients discharged without any opioid included 15 of 26 (57.7%) for parathyroidectomy, 12 of 32 (37.5%) for hemithyroidectomy, and 9 of 27 (33.3%) for total thyroidectomy. No increase in patient calls requesting refills for opioid medications occurred in the group discharged with a lower dose. The data for patients calling for additional pain medication after discharge are shown in Table 3 for each type of procedure. Overall, for group 1, 45 of 1336 (3.4%) called for additional pain medications after discharge, and 8 of 429 (1.9%) of group 2 (95% CI, −0.6% to 3.0%, continuity corrected). Patients undergoing hemithyroidectomy and total thyroidectomy (45 of 1042 [4.3%]) called in more than those undergoing parathyroidectomy 8 of 723 [1.1%]), as shown in Table 3. None of the patients who were prescribed less than 75.0 MME postoperatively called in for additional opioid prescriptions.

Discussion

This retrospective study was conducted to determine opioid prescribing practices and opioid needs in patients who underwent thyroid and parathyroid procedures at a single institution performing high-volume endocrine surgery. We found that opioid prescribing and opioid needs for patients who underwent thyroid and parathyroid surgery can be dramatically reduced through the concerted use of preoperative patient counselling regarding pain management, multimodality nonopioid pain management, working with nursing to assess pain based on functional status rather than a 1- to 10-point scale, and avoiding opioid administration when possible. We also observed tremendous variability in patterns of opioid prescribing on review of our patient data. Part of this variability can be attributed to the fact that the responsibility of opioid prescribing largely falls on the rotating residents and fellows writing the prescriptions for discharge. This process likely resulted in a wide range of doses as well as high doses seen in group 1 patients. Most of the prescribing house officers are from the head and neck surgery service or surgical oncology service, where they may have become accustomed to prescribing higher doses of opioids for larger resections and generally more painful operations compared with thyroid and parathyroid procedures. Therefore, their overprescribing for the endocrine procedures is not surprising. In addition, the use of electronic medical records with preprogrammed postsurgical order sets may also have contributed to the higher amounts in group 1. The use of an automatic opioid order with a large range, such as 5 to 15 mg of oxycodone hydrochloride every 3 hours, appears to be associated with a higher number of pills prescribed. With our electronic medical record system, these orders can be turned into outpatient prescriptions. When creating the prescription, if the option of number of days to prescribe is selected rather than the actual number of pills to prescribe, the prescription automatically calculates the total number of pills based on the higher range. Although the overall prescribed doses for group 2 are significantly lower, we found a wide range in doses prescribed. This range is likely attributed again to prescriptions being written by trainees and to the fact that a few of the surgeons at our institution had yet to move toward the practice of reducing opioid prescribing for endocrine surgery.

Our data suggest that the estimated largest possible difference in the amount of opioid prescribed between groups 1 and 2 is 116.19 MME for hemithyroidectomy, 141.36 MME for total thyroidectomy, and 109.12 MME for parathyroidectomy (the upper bounds of the 95% CI reported). This difference was achieved by instituting preoperative patient counseling, working with perioperative nursing toward the same goal, and educating house officers. The significantly lower doses of opioid prescribed in group 2, particularly during the last 6 months of the study period, suggest that the postoperative opioid need for patients undergoing thyroid and parathyroid procedures is minimal, if at all. The fact that very few patients called back for opioid refills in the group prescribed a lesser quantity supports this. A previous study by Lou and colleagues10 prospectively evaluated the quantity of postoperative opioid requirements after thyroid and parathyroid surgery and found that 83% of these patients took less than 10 MME postoperatively. In the last year, several of our surgeons in our Thyroid and Parathyroid Center at OHSU moved toward reducing opioid prescribing by aggressively pursuing the use of multimodality, nonopioid pain management strategies, such as acetaminophen administration preoperatively and local anesthesia with superficial cervical blocks intraoperatively, while maintaining appropriate pain control for the opioid-naive patients. Several prospective studies have shown the efficacy of intraoperative cervical blocks during thyroidectomy is effective in reducing postoperative opioid needs.11-14 Furthermore, the use of preoperative acetaminophen has also been shown to be effective in reducing postoperative opioid needs.15 Our current postoperative management also focuses on maximizing nonopioid pain management strategies such as liberal use of ice packs, throat lozenges, acetaminophen, and nonsteroidal anti-inflammatory drugs and reserving opioids for severe pain.

In our study, although the mean MME being prescribed was significantly reduced in group 2, the amounts being administered in the postoperative anesthesia care unit varied widely. This approach of judicious use of opioid required cooperation from the perioperative nursing team and educating them on how to better assess the character of postoperative pain in this patient population. It is not uncommon for these patients to have a sore throat due to the larynx rotating around the endotracheal during retraction of the thyroid and tracheal, and posterior neck muscle ache due to neck extension, both of which could be effectively managed without opioids.

The group that was prescribed a lower dose or no opioid appeared to be less likely to call in for a refill. Thirty-four of the 53 patients who called for refills were prescribed more than 100 MME, whereas none of the patients who received less than 75 MME or were not prescribed any opioids at discharge called for an additional or a new opioid prescription. This finding is partly attributed to preoperative education on pain management and setting expectations for opioid prescriptions. Consistent preoperative discussion with the patients about what to expect with respect to postoperative pain and its management occurred most often with the 2 attending surgeons who did not prescribe any opioids. Our results indicate that to successfully implement nonopioid pain management in opioid-naive patients, surgeons need to preoperatively educate the patient regarding postoperative pain expectation and management strategy. Research has shown that effective communication in the preoperative setting can significantly reduce postoperative opioid use and that 90% of patients who were counselled preoperatively and received preoperative oral and written education regarding pain declined opioids postoperatively.16 The ability to electronically prescribe opioids in our institution allows us to address the patient's need promptly after discharge should it be necessary. For institutions that are not allowed to prescribe electronically, sending patients home without any opioids may not be feasible. In that setting, a small quantity of opioid prescription may be necessary. Based on the study by Lou et al,10 approximately 10 to 20 MME would seem reasonable.

Limitations

The main limitation of this study is that, although it captured the prescribed dose, it did not capture the actual quantity of opioid consumed by patients at home. Prospective studies with a large cohort, ideally multi-institutional, that actually capture amount of medication consumed are needed to accurately assess what the true opioid requirements are for thyroid and parathyroid surgery. Developing an opioid prescribing guideline specific to these procedures would allow surgeons to comfortably prescribe just the minimum amount for same-day discharge. Patients receiving opioids for chronic pain are not included in this study and require a different approach to pain management. Our current approach for these patients is to work with the physician managing the patient's pain medication and formulate a plan such that the patient is prescribed very little additional opioids, if any, on discharge. Our institution is currently reviewing the data on this group of patients.

Conclusions

Results of this study suggest that patients undergoing thyroid and parathyroid surgery need very little, if any, postoperative opioids. Preoperative counselling of patients regarding pain and adding nonopioid adjuncts can help to minimize the quantity of opioids that are used. These patients have relatively little postoperative pain that can be potentially controlled entirely with nonopioid medications. Decreasing the volume of opioid medication prescribed at discharge will decrease waste and reduce potential for addiction.

Association of Facility Volume With Positive Margin Rate in the Surgical Treatment of Head and Neck Cancer. | Facial Plastic Surgery | JAMA Otolaryngology–Head & Neck Surgery | JAMA Network

high-volume facilities have lower rates of PM in the surgical treatment of HNSCC in both the academic and nonacademic settings. Despite this discrepancy between high- and low-volume facilities, there is no corresponding difference in the use of guideline-recommended adjuvant CRT. This study underscores the benefits of high-volume HNSCC centers on surgical outcomes and should be a consideration when deciding where to refer, or receive, cancer care. Positive margin rates and facility volume for head and neck oncologic surgeries may be considered a benchmark for quality of care
https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2705980?guestAccessKey=ac36947f-1b29-4151-ae73-343680b7a9d5&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jamaotolaryngology&utm_content=etoc&utm_term=122018

For patients with head and neck squamous cell carcinoma, do positive margin (PM) rates vary according to treatment facility case volume, and are patients referred for chemoradiation therapy if they have PM?

Findings  For this retrospective cohort study, the National Cancer Database was used to identify 28 840 patients with an overall PM rate of 17.6%. In both univariable and multivariable analyses, higher facility volume was associated with a lower PM rate; however, no association was found between facility volume and likelihood of receiving adjuvant chemoradiation therapy in the setting of PM.

Meaning  Facility volume appears to be associated with patient likelihood of receiving a PM resection.

Abstract

Importance  The achievement of complete tumor resection with tumor-free margins is one of the main principles of oncologic surgery for head and neck squamous cell carcinoma (HNSCC). The negative prognostic influence of a positive margin (PM) across all head and neck subsites has been well established. National guidelines recommend the use of adjuvant chemoradiation therapy (CRT) in the setting of PM.

Objective  To determine the incidence of PM in HNSCC across multiple subsites, as well as the factors associated with its occurrence.

Design, Setting, and Participants  This retrospective cohort study used the National Cancer Database to identify patients diagnosed with HNSCC between 2010 and 2014 and who underwent surgical resection (n = 28 840).

Main Outcomes and Measures  Predictors of PM rate and likelihood to receive adjuvant CRT.

Results  Among the 28 840 patients included in this study, 19 727 (68.4 %) were men, and the average age was 62.4 years (range, 40 to ≥90 years). In univariable analysis, a lower PM rate was associated with higher facility volume (26.3% for the lowest volume quartile, 16.5% for the middle 2 quartiles, and 10.8% for the highest volume quartile) and treatment at academic vs nonacademic facilities (14.0% vs 22.7%). In multivariate analysis, those treated at higher-volume facilities remained significantly less likely to have PM (adjusted odds ratio, 0.85; 95% CI, 0.83-0.88). The trend of decreasing PM rate with increasing facility volume was observed in both academic (aOR, 0.88 per 10-case volume increase [95% CI, 0.85-0.91]) and nonacademic (aOR, 0.73 per 10-case volume increase [95% CI, 0.68-0.80]) facilities. There was no association between facility volume and patient likelihood of receiving adjuvant CRT in the setting of PM (compared with CCPs: aOR, 0.98 per 10-case volume increase [95% CI, 0.84-1.14] for CCCPs; and aOR, 1.24 [95% CI, 0.99-1.55] for INCPs).

Conclusions and Relevance  These findings suggest that high-volume facilities are associated with lower rates of PM in the surgical treatment of HNSCC in both academic and nonacademic settings. Facility volume for head and neck oncologic surgeries may be considered a benchmark for quality of care.

Introduction

One of the main principles of head and neck oncologic surgery is the achievement of complete tumor resection and tumor-free margins.1 The negative prognostic effect of a positive margin (PM) in head and neck squamous cell carcinoma (HNSCC) has been well established.2-7 Although there are a number of pathologic features that place patients at high risk for local recurrence (eg, involved lymph nodes, extracapsular extension, perineural and lymphovascular invasion), PM is the only one that has potential for intraoperative modification. If PM is identified after surgical resection of HNSCC, National Comprehensive Cancer Network (NCCN) guidelines recommend the use of adjuvant chemoradiation therapy (CRT).

There are growing data in head and neck cancer literature on the association between outcomes and surgery-related factors. Large population-based studies have demonstrated positive associations between survival rates and surgical case volume, of both the surgeon and the treating hospital.8,9Furthermore, the influence of the type of treating hospital has also been studied, with academic facilities producing better outcomes than nonacademic facilities among patients treated with adjuvant radiation therapy.10,11 Regarding PM and surgery-related factors, a high rate of PM has been associated with treatment at nonacademic facilities and institutions with low oral cancer case volume, but these studies are limited in scope with respect to head and neck subsites and staging.12,13

Using a contemporary data set, our aim was to determine the incidence of PM in HNSCC of all stages across multiple subsites and the factors associated with PM occurrence. We hypothesized that margin status is associated with treatment facility characteristics and that the prescription of adjuvant CRT is different across facility types.

Methods
Data Source

Data for this study came from the National Cancer Database (NCDB), a joint project of the American Cancer Society and the American College of Surgeons Commission on Cancer (CoC). The database captures more than 80% of newly diagnosed head and neck cancers from approximately 1500 CoC-accredited facilities around the United States.14 The NorthShore University HealthSystem Institutional Review Board granted this study exempt status, and patient informed consent was waived because the study was retrospective and data from the NCDB were deidentified.

Study Cohort

We identified patients diagnosed with invasive HNSCC from 2010 through 2014 who were then treated with definitive surgery. The cohort was limited to patients with clinical stage I through IVB tumors (excluding those with clinical T4b disease) of the oral cavity, oropharynx, larynx, and hypopharynx, based on the American Joint Committee on Cancer 7th edition.15 Those with grade 4 tumors, other invasive malignancies, and unknown or indeterminate margin status; who underwent local tumor destruction or biopsy; and who received care at facilities other than the diagnosing facility were excluded. We restricted the cohort to patients who received surgery at the facility that reported their cases to the NCDB. Finally, those younger than 40 years were excluded, because data on the type of treating facility (eg, academic, community) is unavailable in the NCDB for those younger than 40 years. We identified approximately 2900 patients (10.2% of the entire cohort) with TX listed for their pathologic T category. We ran a sensitivity analysis excluding this TX cohort and found that it did not affect the results.

Statistical Analysis

Unadjusted risk ratios for PM, with corresponding 95% CIs, were computed for demographic, clinical, and facility factors. Demographic factors included age, sex, race/ethnicity, insurance, and socioeconomic status (from an aggregate of county-level median income and education). Clinical factors included the Charlson-Deyo comorbidity score,16 primary site, tumor grade, clinical grouped TNM stage, pathologic T category, and pathologic N category. Facility characteristics included the facility mean annual surgical volume (grouped into <25th, 25th-75th, and >75th percentiles), facility location, and facility type (ie, academic, nonacademic). Nonacademic facilities were characterized by their lack of residency training program requirements and were categorized according to their annual caseloads. Nonacademic facilities included community cancer programs (CCPs) (100-500 new cases per year), comprehensive community cancer programs (CCCPs) (>500 new cases per year), and integrated network cancer programs (INCPs) (organization with multiple facilities related to cancer care, 1 of which is a CoC-accredited hospital; no minimum caseload). Surgical margins were coded into the NCDB as negative, positive (divided into macroscopic residual tumor, microscopic residual tumor, and residual tumor not otherwise specified), indeterminate, or not available/unknown. Margin status was coded as it appeared in the pathology report of the reporting facility.

Multivariable analysis of predictors of PM was performed using a generalized estimating equation model with logit link and exchangeable correlation structure, accounting for patient clustering at facilities and adjusting for the same demographic, clinical, and facility factors as in the univariable analysis. Facility volume was treated as a continuous variable in this analysis. We predicted average marginal effects of facility volume from this model as the probability of PM and plotted this along with true observed PM rates to directly compare unadjusted and adjusted volume-outcome relationships.

To evaluate whether the facility volume effect was influenced by facility type, we computed a multivariable generalized estimating equation model that allowed for an interaction between facility volume and facility type (ie, academic, nonacademic). We then plotted predicted and observed probabilities of PM across facility volume (separately for academic and nonacademic facilities), as previously described.

Finally, we assessed the association of facility volume with the likelihood of receiving adjuvant CRT among patients with PM, using a multivariable generalized estimating equation model. Predicted and observed probabilities of receiving CRT were then plotted across facility volume.

All analysis was performed using Stata, version 14.2 (StataCorp). All tests were 2 sided, and P < .05 was considered statistically significant.

Results

We identified 28 840 patients who met selection criteria. Characteristics of the final cohort are detailed in Table 1. The overall PM rate was 17.6%, and the average age was 62.4 years (range, 40 to ≥90 years). A majority of patients were white (84.6% [n = 24 399]) and had no additional comorbidities (74.0% [n = 21 342]). The most common primary site was the oral cavity (53.7% [n = 15 487]), followed by the oropharynx (26.0% [n = 7498]), larynx (18.8% [n = 5422]), and hypopharynx (1.5% [n = 433]). The average annual facility caseload was 29.0, and the majority of facilities were academic (59.0% [n = 17 016]).

Predictors of PM

Risk ratios (RR) of PM according to patient and facility characteristics are detailed in Table 2. Patients who were younger; male; black; had Medicaid insurance; had primary sites of the oropharynx, hypopharynx, or larynx; and had higher tumor grade or TNM stage were all significantly more likely to have PM. Higher facility volume was associated with lower PM rate (compared with the lowest-volume quartile: RR, 0.63 [95% CI, 0.59-0.66] for the middle 2 quartiles; and RR, 0.41 [95% CI, 0.38-0.44] for the highest-volume quartile). Patients treated at academic facilities had a PM rate of 14%. Among nonacademic facilities, CCPs had a PM rate of 28.2%, CCCPs had 22.8%, and INCPs had 19.3%. Patients treated at academic facilities were significantly less likely to have PM (compared with CCPs with the highest rate of PM: RR, 0.50 [95% CI, 0.45-0.54]).

In multivariable analysis, those treated at higher-volume facilities remained significantly less likely to have PM (Figure 1) (adjusted odds ratio [aOR], 0.85 per 10-case volume increase [95% CI, 0.83-0.88]). Importantly, the predicted likelihood of PM decreased with increasing facility volume and closely matched the observed likelihood of PM. The predicted and observed likelihoods were approximately 20% for patients at facilities with 10 annual cases and as low as 10% at facilities with 70 annual cases. The trend of decreasing PM rate with increasing facility volume was observed in both academic (Figure 2A) (aOR, 0.88 per 10-case volume increase [95% CI, 0.85-0.91]) and nonacademic (Figure 2B) (aOR, 0.73 per 10-case volume increase [95% CI, 0.68-0.80]) facilities, despite substantial differences in the distributions of volume between these types of facilities. There was no association between facility volume and PM among the different types of nonacademic facilities (compared with CCPs: aOR, 0.98 per 10-case volume increase [95% CI, 0.84-1.14] for CCCPs; and aOR, 1.24 [95% CI, 0.99-1.55] for INCPs).

Receipt of Adjuvant Chemoradiation Therapy for PM

In contrast, we observed no association between facility volume and patient likelihood of receiving adjuvant CRT in the setting of PM (Figure 3) (aOR, 0.96 per 10-case volume increase [95% CI, 0.91-1.00]). This was true among both the observed data and the probabilities predicted by the multivariable model. Notably, the predicted likelihood of receiving CRT in the setting of PM was less than 50% regardless of facility volume.

Discussion

We found that surgical treatment for HNSCC at a low-volume facility was associated with an increased likelihood of PM. This association persisted whether surgery was performed at an academic or nonacademic facility, despite overall volume differences between these 2 types of facilities. We found no association between facility volume and the use of adjuvant CRT in the setting of PM.

The present study focused on the influence of volume on the surgical outcome of PM, a clear measure of surgical success and patient prognosis. The findings of this study contribute to the growing body of literature examining the association between surgical volume and outcomes in head and neck oncology.17 In studies limited to single head and neck subsites, high-volume hospitals and surgeons have been found to be associated with improved survival, shorter hospitalization stays, lower cost of care, and lower complication rates.8,18-21 It has been suggested that high-volume facilities and surgeons benefit from the coordination of a large, experienced team of specialists who are properly equipped and trained to care for patients with complex head and neck cancer.8

Surgical Volume and PM

Among the high-risk features in HNSCC, PM is the only one in which the surgeon has some control, independent of facility factors. Previously published studies examining the relationship between volume and PM have only included oral cavity cancers.12,13,22 A recent study by Ellis et al12 on oral cavity cancer found that higher-volume surgeons delivered larger surgical margins than lower-volume surgeons and that surgeon volume had the single greatest influence on surgical margin dimensions. This has important clinical implications because, according to NCCN guidelines, surgery is the recommended primary treatment modality for oral cavity cancer.1 In contrast to that study, which included only 250 patients with oral cancer from a single institution, the present study included nearly 30 000 patients with HNSCC from a national database. An older oral cancer study found a close association between a close margin or PM and histological indicators of aggressive disease, although not with the treating surgeon.22 However, that study only included 2 surgeons and did not define their caseloads. The authors argued that a close margin or PM should be considered "a product of aggressive tumor behavior in addition to, or even rather than, inadequate surgical resection."22(p34) However, aggressive tumor biology should not be a reason to forgo a more radical surgery or deem a patient unresectable, especially with the reconstructive options currently available to help reduce the cosmetic and functional morbidity of such resections.

A similar NCDB analysis of PM in localized stage oral cancers (stage I/II) was performed by Luryi et al.13 The authors found that treatment at low-volume facilities and at nonacademic facilities was associated with an independent increase in the risk of PM. Treatment at facilities reporting fewer than 20 cases per year was associated with a 30% increase in incidence of PM compared with those reporting more than 20 cases per year. Similarly, treatment at nonacademic facilities was associated with a 23% increase in PM compared with academic facilities. However, that study was limited to only localized stage oral cavity cancer from an older data set. The present study adds to the current literature by using a large, contemporary data set and including all TNM stages and head and neck subsites.

Positive Margin and Guidelines Adherence

The present study found that facility volume was not associated with the use of adjuvant CRT in the setting of PM. We demonstrated that the overall likelihood of receiving CRT was approximately 50%. The use of adjuvant CRT in the setting of PM following surgery for HNSCC is a category 1 recommendation according to NCCN guidelines (except for oropharynx primary cancer, which is a category 2a recommendation).1 Moreover, a recent analysis of the NCDB by our group confirmed a significant survival benefit with the use of adjuvant CRT in patients who have PM after surgery.23 Our CRT analysis is exploratory and did not evaluate its administration by site or stage, but our findings highlight concerns over guideline adherence in the management of head and neck cancer and requires further investigation.

Lewis et al24 found that prereferral care among patients referred to the University of Texas MD Anderson Cancer Center, a high-volume, tertiary care center, was noncompliant with NCCN guidelines in 43% of patients. Remarkably, 10.9% received inadequate adjuvant therapy. In contrast, Hessel et al25 found an overall very high rate of guideline adherence at MD Anderson Cancer Center, with 98% of patients appropriately referred to the Radiation Oncology division when high-risk features on pathology were identified. In their population-based analysis, Eskander et al26 found that higher hospital and surgeon volumes for head and neck cancer were associated with higher rates of adherence to guideline-recommended processes of care. Such findings underscore the potential value of highly specialized referral centers with high caseloads for the proper management of HNSCC.

Other Factors Associated With PM

The availability of frozen sections has been evaluated for its potential influence on surgical margins. Frozen sections provide preliminary margin status intraoperatively with the goal of achieving definitive clear margins. Although frozen sections are highly accurate in the evaluation of margins for HNSCC,27 the selection of representative margins for intraoperative analysis—whether from the tumor bed or main specimen—and its effect on recurrence and survival is still an area of contention.28,29 It also adds to the operative time and incurs extra service costs. The availability of frozen sections during the surgical resection of HNSCC could theoretically lower the rate of PM, but there is conflicting evidence in the literature that neither supports nor refutes this relationship.12

The availability of a reconstructive surgeon, with the ability to perform microvascular free flap reconstruction, is another potential factor that can influence margin status. It can be hypothesized that the availability of microvascular free tissue transfer allows for a more aggressive tumor resection to achieve clear margins, despite the potential creation of extensive functional and cosmetic defects. In 2 small retrospective studies on surgically resectable oral cavity squamous cell carcinoma,12,30 no association was found between the presence of PM and reconstruction with free tissue transfer, as opposed to a locoregional flap. A large retrospective study on only T3 and T4 category oral cancers,31 however, showed a significant decrease in the rate of PM (from 18% to 7%) after the introduction of routine free flap reconstruction. It may be that the larger ablative surgeries required for locally advanced HNSCC are more likely to be limited in scope if free flap reconstruction is not available. Such may be the scenario at lower-volume hospitals where the low caseload does not attract or warrant the hiring of reconstructive surgeons, or justify supporting patients' complex postoperative care needs.

Limitations

The availability of intraoperative margin analysis and a reconstructive surgeon are possible confounding factors that are not included in our analysis, because these datapoints are not available in the NCDB. There are several other important limitations to our work. As a retrospective observational study, it is difficult to draw any causal conclusions about observed associations. The NCDB is also a facility-based data set that only captures cancers diagnosed at CoC-accredited facilities, which may not reflect trends in oncologic outcomes for non–CoC-accredited facilities. Importantly, there is no universally accepted definition of what constitutes a negative, close, or positive margin, which makes it challenging to compare surgical outcomes among different facilities.6 This ambiguity can lead to database coding errors and can bias the choice of adjuvant therapy at individual treating centers. The margin status reported in the NCDB is taken from the pathology report from the reporting facility. It is not necessarily reflective of the margin status as determined by the surgeon or from a multidisciplinary tumor board discussion, where decisions regarding adjuvant therapy are often made. Finally, we are unable to evaluate the relationship between PM and surgeon volume, treated separately from hospital volume, as this information is not available in the NCDB.

Conclusions

These findings suggest that high-volume facilities have lower rates of PM in the surgical treatment of HNSCC in both the academic and nonacademic settings. Despite this discrepancy between high- and low-volume facilities, there is no corresponding difference in the use of guideline-recommended adjuvant CRT. This study underscores the benefits of high-volume HNSCC centers on surgical outcomes and should be a consideration when deciding where to refer, or receive, cancer care. Positive margin rates and facility volume for head and neck oncologic surgeries may be considered a benchmark for quality of care.

The Medicare Access and CHIP Reauthorization Act of 2015 for Medical and Radiation Oncologists

This review describes the structure and requirements of the Medicare Access and CHIP [Children's Health Insurance Program] Reauthorization Act of 2015 and how it affects reimbursement for medical and radiation oncologists.

https://ift.tt/2SbyejT

Αναζήτηση αυτού του ιστολογίου